Back to All Combinations

RAS Mutant + Right-Sided

Poor Prognosis
20.00% Prevalence Level 2A Tumor Location
Genes Involved
KRAS NRAS
Treatment Implications

Double negative prognostic factors. Aggressive biology.

Recommended Treatments
FOLFOXIRI + Bevacizumab
Clinical trials
Treatments to Avoid
Anti-EGFR
Study References

TRIBE subgroups

Key Statistics
20.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Poor prognosis warrants aggressive approach.
Information

Category: Tumor Location

Evidence Level: Level 2A

Last Updated: Dec 7, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.